CN115529816A - 使用(R)-N-(3-氟-4-((3-((1-羟基丙-2-基)氨基)-1H-吡唑并[3,4-b]吡啶-4-基)氧基)苯基)-3-(4-氟苯基)-1-异丙基-2,4-二氧-1,2,3,4-四氢嘧啶-5-甲酰胺治疗癌症的方法 - Google Patents

使用(R)-N-(3-氟-4-((3-((1-羟基丙-2-基)氨基)-1H-吡唑并[3,4-b]吡啶-4-基)氧基)苯基)-3-(4-氟苯基)-1-异丙基-2,4-二氧-1,2,3,4-四氢嘧啶-5-甲酰胺治疗癌症的方法 Download PDF

Info

Publication number
CN115529816A
CN115529816A CN202180027637.8A CN202180027637A CN115529816A CN 115529816 A CN115529816 A CN 115529816A CN 202180027637 A CN202180027637 A CN 202180027637A CN 115529816 A CN115529816 A CN 115529816A
Authority
CN
China
Prior art keywords
compound
cancer
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027637.8A
Other languages
English (en)
Chinese (zh)
Inventor
K·S·布哈纳
J·Y-F·翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN115529816A publication Critical patent/CN115529816A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180027637.8A 2020-03-03 2021-03-01 使用(R)-N-(3-氟-4-((3-((1-羟基丙-2-基)氨基)-1H-吡唑并[3,4-b]吡啶-4-基)氧基)苯基)-3-(4-氟苯基)-1-异丙基-2,4-二氧-1,2,3,4-四氢嘧啶-5-甲酰胺治疗癌症的方法 Pending CN115529816A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US62/984,458 2020-03-03
US202163133501P 2021-01-04 2021-01-04
US63/133,501 2021-01-04
PCT/IB2021/051693 WO2021176330A1 (en) 2020-03-03 2021-03-01 Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Publications (1)

Publication Number Publication Date
CN115529816A true CN115529816A (zh) 2022-12-27

Family

ID=74860342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027637.8A Pending CN115529816A (zh) 2020-03-03 2021-03-01 使用(R)-N-(3-氟-4-((3-((1-羟基丙-2-基)氨基)-1H-吡唑并[3,4-b]吡啶-4-基)氧基)苯基)-3-(4-氟苯基)-1-异丙基-2,4-二氧-1,2,3,4-四氢嘧啶-5-甲酰胺治疗癌症的方法

Country Status (12)

Country Link
US (1) US20230117328A1 (https=)
EP (1) EP4114397A1 (https=)
JP (2) JP7181325B2 (https=)
KR (1) KR20220148867A (https=)
CN (1) CN115529816A (https=)
AU (1) AU2021231435A1 (https=)
BR (1) BR112022017267A2 (https=)
CA (1) CA3174064A1 (https=)
IL (1) IL296060A (https=)
MX (1) MX2022010955A (https=)
TW (2) TWI814504B (https=)
WO (1) WO2021176330A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209457A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Combination Therapy
CN112930215A (zh) * 2018-08-30 2021-06-08 阿雷生物药品公司 作为TAM和MET激酶抑制剂的吡唑并[3，4-b]吡啶化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US10329570B2 (en) 2014-07-31 2019-06-25 Academia Sinica Antagonistic PD-1 aptamer and its applications in cancer therapy related applications
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209457A1 (en) * 2014-07-31 2017-07-27 Novartis Ag Combination Therapy
CN112930215A (zh) * 2018-08-30 2021-06-08 阿雷生物药品公司 作为TAM和MET激酶抑制剂的吡唑并[3，4-b]吡啶化合物

Also Published As

Publication number Publication date
US20230117328A1 (en) 2023-04-20
TWI814504B (zh) 2023-09-01
JP2021138693A (ja) 2021-09-16
JP7181325B2 (ja) 2022-11-30
EP4114397A1 (en) 2023-01-11
TW202317125A (zh) 2023-05-01
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
TWI775333B (zh) 2022-08-21
BR112022017267A2 (pt) 2022-12-13
TW202146025A (zh) 2021-12-16
JP2023009250A (ja) 2023-01-19
KR20220148867A (ko) 2022-11-07
CA3174064A1 (en) 2021-09-10
WO2021176330A1 (en) 2021-09-10
MX2022010955A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
JP6742391B2 (ja) 併用療法
TWI607754B (zh) 醫藥組合
BR112019021880A2 (pt) Terapia de combinação com conjugado anticorpo anti-axl-droga
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
BR112015026297B1 (pt) Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
CN119997942A (zh) 用于治疗癌症的化合物
TWI814504B (zh) 治療癌症之方法
AU2024404811A1 (en) Anti-cancer combination therapy
JP2026501925A (ja) Ｈｅｒ２阻害剤の固体分散剤の投与スケジュール
HK40079302A (en) Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
US20260034134A1 (en) Treatment of cancer with metastases in the central nervous system
WO2024263960A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263966A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731199A2 (en) Compositions comprising antineoplastons and methods of treating colorectal cancer
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
HK40051622A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40107241A (zh) 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
HK40028739A (en) Methods and combination therapy to treat cancer
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079302

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221227

WD01 Invention patent application deemed withdrawn after publication